Industry news that matters to you.  Learn more

Archives for September 2012

GVK Biosciences licenses its Biomarker Database to The Division of Cancer Prevention, National Cancer Institute

GVK Biosciences (GVK BIO), Asia’s leading contract research organization announced recently that it has licensed its popular clinical biomarker database (GOBIOM) to the prestigious Division of Cancer Prevention (DCP), National Cancer Institute (NCI).

Saladax Biomedical, Inc. Expands Distribution of MyCare™ Products in Israel

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced yesterday that Ilex Medical Ltd. will serve as exclusive distributor of Saladax’s My5-FU™, MyPaclitaxel™ and MyDocetaxel™ diagnostic reagent kits throughout the Israeli market. The MyCare™ tests are designed to measure levels of these common chemotherapy drugs in the blood of cancer patients to overcome the limitations associated with dosing based on body surface area (BSA).

The Foundation for the NIH Biomarkers Consortium Launches A Multi-Stakeholder Atherosclerosis Modeling Project

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium announces that it is launching a two-year effort to use computer modeling to better understand heart disease and the potential effectiveness of medicines used to treat it. The project will integrate large amounts of available information on different measures (or “biomarkers”) of atherosclerosis.

Merck Serono Announces the Creation of Quartz Bio, a Biomarker Bioinformatics Company

Merck Serono, a division of Merck, Darmstadt, Germany, announced today the creation of Quartz Bio, the second spin-off company resulting from its Entrepreneur Partnership Program launched in April 2012. Quartz Bio will offer biomarker data management and exploratory biomarker analysis services for the pharmaceutical industry. Biomarker analysis is a critical step in the drug development process as it enables the identification of patient profiles that are most responsive to a given treatment.